Company Profiles

driven by the PitchBook Platform

Ark Biosciences

Description

Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis. The company's leading drug AK0529 specifically inhibits RSV (Respiratory Syncytial Virus) replication by blocking viral entry and syncytial formation, providing an effective first-line antiviral therapy for RSV infection in infants and the elderly.

2014

Founded

PRIVATE

Status

Series A

Latest Deal Type

5

Investors

Description

Developer of innovative therapeutics created to address unmet medical needs in the area of respiratory viral infection and viral hepatitis. The company's leading drug AK0529 specifically inhibits RSV (Respiratory Syncytial Virus) replication by blocking viral entry and syncytial formation, providing an effective first-line antiviral therapy for RSV infection in infants and the elderly.

Website:

www.arkbiosciences.com

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Pharmaceuticals
Biotechnology

Primary Office

Room 701, 780 Cailun Road Pudong New Area Shanghai, 201203China +86 (0)21 5835 0139
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Ark Biosciences's full profile, request a free trial.

    Ark Biosciences Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Ark Biosciences Investors (5)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Bioventure InvestmentVenture CapitalMinority000 0000000 0000
    Morningside GroupVenture CapitalMinority000 0000000 0000
    Oriza VenturesVenture CapitalMinority000 0000000 0000
    Qiming Venture PartnersVenture CapitalMinority000 0000000 0000
    TF CapitalVenture CapitalMinority000 0000000 0000
    Bioventure Investment Venture Capital
    Morningside Group Venture Capital
    Oriza Ventures Venture Capital
    Qiming Venture Partners Venture Capital
    TF Capital Venture Capital

    Ark Biosciences Executive Team (4)

    NameTitleBoard
    Seat
    Contact
    Info
    Jim Wu Ph.DChief Executive Officer & Founder
    Hong QinVice President
    Stephen Toovey Ph.DChief Medical Officer
    Gianni Gromo Ph.DScientific Advisor
    Jim Wu Ph.D Chief Executive Officer & Founder
    Hong Qin Vice President
    Stephen Toovey Ph.D Chief Medical Officer
    Gianni Gromo Ph.D Scientific Advisor
    Request full access to PitchBook